Immune‐Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis
Authors:
Open Access
- 24 June 2020
- journal article
- editorial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 73 (1) , 460-463
Abstract
Increased use of novel immunomodulatory agents has led to emerging forms of drug‐induced liver injury. Alemtuzumab is a recombinant, humanized monoclonal antibody against CD52, which is present on T cells, B cells, monocytes and natural killer cells. A single dose results in a depletion of the entire lymphocyte population followed by varied kinetics in the recovery of each cell type. Alemtuzumab has been approved as an immune reconstitution therapy in relapsing and remitting multiple sclerosis (RRMS). Since its approval, cases of acute hepatitis have been documented but reports of delayed‐onset immune‐mediated hepatitis with recurrent episodes of liver failure following treatment with alemtuzumab have not been published.Keywords
This publication has 5 references indexed in Scilit:
- Acute severe hepatitis with alemtuzumab and rechallenge after a yearJournal of Clinical Neuroscience, 2019
- Sarcoidosis following alemtuzumab treatment for multiple sclerosisMultiple Sclerosis Journal, 2018
- Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological FeaturesThe Journal of Clinical Endocrinology & Metabolism, 2018
- Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumabActa Neurologica Belgica, 2018
- Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosisExpert Review of Neurotherapeutics, 2012